Protein Kinase CK2 Expression Predicts Relapse Survival in ER? Dependent Breast Cancer, and Modulates ER? Expression in Vitro

Marlon D. Williams, Thu Nguyen, Patrick P. Carriere, Syreeta L. Tilghman and Christopher Williams
Additional contact information
Marlon D. Williams: College of Pharmacy, Xavier University of Louisiana, 1 Drexel Dr, New Orleans, LA 70125, USA
Thu Nguyen: College of Pharmacy, Xavier University of Louisiana, 1 Drexel Dr, New Orleans, LA 70125, USA
Patrick P. Carriere: College of Pharmacy, Xavier University of Louisiana, 1 Drexel Dr, New Orleans, LA 70125, USA
Syreeta L. Tilghman: Division of Basic Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida Agricultural & Mechanical University, 1415 S. Martin L. King Jr. Blvd., Tallahassee, FL 32307
Christopher Williams: College of Pharmacy, Xavier University of Louisiana, 1 Drexel Dr, New Orleans, LA 70125, USA

IJERPH, 2015, vol. 13, issue 1, 1-9

Abstract: The heterotetrameric protein kinase CK2 has been associated with oncogenic transformation, and our previous studies have shown that it may affect estrogenic signaling. Here, we investigate the role of the protein kinase CK2 in regulating ER? (estrogen receptor ?) signaling in breast cancer. We determined the correlation of CK2? expression with relapse free breast cancer patient survival utilizing Kaplan Meier Plotter (kmplot.com/analysis/) to mine breast cancer microarrays repositories. Patients were stratified according to ER? status, histological grade, and hormonal therapy. Luciferase reporter assays and flow cytometry were implemented to determine the impact of CK2 inhibition on ERE-mediated gene expression and expression of ER? protein. CK2? expression is associated with shorter relapse free survival among ER? (+) patients with grade 1 or 2 tumors, as well as among those patients receiving hormonal therapy. Biochemical inhibition of CK2 activity results in increased ER-transactivation as well as increased expression among ER? (+) and ER? (?) breast cancer cell lines. These findings suggest that CK2 may contribute to estrogen-independent cell proliferation and breast tumor progression, and may potentially serve as a biomarker and pharmacological target in breast cancer.

Keywords: CK2; estrogen receptor (ER?); relapse free survival; breast cancer (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2015
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/13/1/36/pdf (application/pdf)
https://www.mdpi.com/1660-4601/13/1/36/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:13:y:2015:i:1:p:36-:d:61075

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().